Mortality Down Only for Gastric Bypass Patients With Diabetes

Share this content:
Mortality Down Only for Gastric Bypass Patients With Diabetes
Mortality Down Only for Gastric Bypass Patients With Diabetes

MONDAY, Aug. 7, 2017 (HealthDay News) -- Patients undergoing Roux-en-Y gastric bypass (RYGB) with diabetes have reduced mortality compared with matched controls, according to a study published online July 31 in Diabetes Care.

Michelle R. Lent, Ph.D., from Geisinger Clinic in Danville, Pa., and colleagues matched RYGB patients by age, body mass index, sex, and diabetes status at time of surgery to nonsurgical controls using electronic health record data. The authors examined differences in all-cause and specific-cause mortality between RYGB patients and controls with and without diabetes.

The researchers identified controls for 2,428 of the 3,242 eligible RYGB patients (625 with and 1,803 without diabetes). RYGB patients had reduced all-cause mortality compared with controls only among those with diabetes at the time of surgery (adjusted hazard ratio, 0.44; P < 0.0001). Compared with controls without diabetes, RYGB patients without diabetes did not have significantly improved mortality (adjusted hazard ratio, 0.84; P = 0.37). Compared to RYGB patients with diabetes, control subjects with diabetes more often had deaths from cardiovascular diseases (P = 0.011), respiratory conditions (P = 0.017), and diabetes (P = 0.011).

"All-cause mortality benefits of RYGB are driven predominantly by patients with diabetes at the time of surgery," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »